Recent reports on the use of tocilizumab (an anti-IL6R monoclonal antibody) in MG have emerged, generally showing efficacy (evidenced by reductions in MG-ADL and QMG scores), alongside an acceptable safety profile (Yang et al., 2023; Jia et al., 2024; Ruan et al., 2024). This evidence concerns the gene IL6R and myasthenia gravis.